The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Sagimet Biosciences Inc. (NASDAQ:SGMT) is one of the 10 best stocks under $10 that could triple.

On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution incorporates about 4,000 of the largest U.S. companies, based on their market capitalization as of the April 30 close.

M. A. Arkhipov/Shutterstock.com

Inclusion in the Russell 3000 Index results in automatic addition to either the Russell 1000 Index or the Russell 2000 Index. It also leads to inclusions across indexes that cover value or growth tilts.

CEO David Happel said this development speaks volumes about what Sagimet has achieved over the years, with people now expecting the company to start its Phase 3 clinical study on denifanstat. He further stated:

"If approved, denifanstat would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years. With the capital in place to fund our programs through 2028, including data readout of our planned denifanstat Phase 3 clinical trial in acne, we look forward to the broader visibility that inclusion in the Russell indexes brings."

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a biopharmaceutical firm at the clinical stage making drug innovations based on fatty acid synthase. The company's leading drug candidate is Denifanstat, which is an oral pill taken once a day to counter diseases associated with the malfunctioning of metabolic processes.

While we acknowledge the potential of SGMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.